Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma Meeting Abstract


Authors: Wolchok, J. D.; Thomas, L.; Bondarenko, I. N.; O'Day, S.; Weber, J. S.; Garbe, C.; Francis, S.; Ibrahim, R. A.; Hoos, A.; Robert, C.
Abstract Title: Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 18 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-06-20
Language: English
ACCESSION: WOS:000208865800021
PROVIDER: wos
DOI: 10.1200/jco.2011.29.18_suppl.lba5
Notes: Meeting Abstract: LBA5 -- Source: Wos
Altmetric Score
MSK Authors
  1. Jedd D Wolchok
    669 Wolchok